Analyst Research

Report Title Price
Provider: MacroRisk Analytics/EconomicInvestor
$25.00
Provider: ValuEngine, Inc.
$25.00
Provider: Finlabo SIM Spa
$10.00
Provider: S&P Capital IQ – STARS Reports
$127.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Fresenius Medical Care AG & Co KGaA Reconfirms Its FY 2013 Guidance In Line With Analysts' Estimates


Tuesday, 5 Nov 2013 01:50am EST 

Fresenius Medical Care AG & Co KGaA announced that it expects revenue to grow to more than USD 14.6 billion in 2013, translating into a growth rate of more than 6%. Net income attributable to shareholders of Fresenius Medical Care AG & Co. KGaA is expected to be between USD 1.1 billion and USD 1.15 billion in 2013, likely at the low end of the range. For 2013, the Company expects to spend around USD 700 million on capital expenditures and around USD 500 million on acquisitions. The debt/EBITDA ratio is expected to be equal or below 3.0 by the end of 2013. According to I/B/E/S Estimates, analysts on average are expecting te Company to report for fiscal year 2013 revenues of USD 14.6 billion with a growth rate of 5.8%, net income of USD 1.104 billion and capital expenditures of USD 732.78 million.